article · Lasers in Medical Science
Breast cancer is the second most common cancer globally and the leading cause of cancer-related deaths in women. Current treatments, such as chemotherapy and surgery, often have side effects and can lead to drug resistance. Developing new treatments that specifically target cancer cells while minimizing side effects is essential. Combining traditional cancer treatments with photodynamic therapy (PDT) is a promising approach. This study evaluated the effectiveness of femtosecond laser-driven PDT using Doxorubicin (DOX) and tetrakis (1-methylpyridinium-4-yl) porphyrin (TMPyP), both individually and in combination, on MDA-MB-231 and T47D breast cancer cells. TMPyP-PDT and DOX monotherapy both exhibited dose-dependent cytotoxicity. However, combination therapy was more effective at lower DOX concentrations, potentially reducing side effects. This combination also increased reactive oxygen species (ROS) levels, inhibited angiogenesis by reducing TGF-β and VEGFA expression, and induced apoptosis by decreasing BCL-2 and increasing BAX levels compared to individual treatments. These findings suggest that combining TMPyP-mediated PDT with Doxorubicin could effectively inhibit breast cancer cell growth.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.1007/s10103-025-04466-z
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
